Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/177787
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pérez de José, Ana | - |
dc.contributor.author | Carbayo, Javier | - |
dc.contributor.author | Pocurull, Anna | - |
dc.contributor.author | Bada Bosch, Teresa | - |
dc.contributor.author | Cases Corona, Clara Maria | - |
dc.contributor.author | Shabaka, Amir | - |
dc.contributor.author | Ramos Terrada, Natàlia | - |
dc.contributor.author | Martínez Valenzuela, Laura | - |
dc.contributor.author | Huerta, Ana | - |
dc.contributor.author | Fernandez Lorente, Loreto | - |
dc.contributor.author | Malek Marín, Tamara Gelen | - |
dc.contributor.author | Goicoechea, Marian | - |
dc.date.accessioned | 2021-05-28T10:09:53Z | - |
dc.date.available | 2021-05-28T10:09:53Z | - |
dc.date.issued | 2020-01-25 | - |
dc.identifier.uri | http://hdl.handle.net/2445/177787 | - |
dc.description.abstract | Background: Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC. Methods: The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological and virological responses after antiviral treatment. Results: Patients were divided into three groups based on the treatment received: treatment with DAAs (n = 100) treatment with interferon (IFN) and ribavirin (RBV) (n = 24) and no treatment (n = 15). Patients were followed up for a median duration of 138 months (interquartile range 70-251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence interval (CI) 0.04-0.40]; P < 0.001} and improved kidney survival [HR 0.10 ( 95% CI 0.04-0.33); P < 0.001]. Conclusions: Results from the RENALCRYOGLOBULINEMIC study indicated that DAA treatment in patients with HCV-MC improves kidney survival and reduces mortality. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Oxford University Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1093/ckj/sfz178 | - |
dc.relation.ispartof | Clinical Kidney Journal, 2020, vol. 14, num. 2, p. 586-592 | - |
dc.relation.uri | https://doi.org/10.1093/ckj/sfz178 | - |
dc.rights | cc by-nc (c) Pérez de José et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Hepatitis C | - |
dc.subject.classification | Malalties del ronyó | - |
dc.subject.other | Hepatitis C | - |
dc.subject.other | Kidney diseases | - |
dc.title | Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-05-28T06:34:08Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33623683 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
sfz178.pdf | 454.65 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License